September 21, 2017
AG Saugmandsgaard Øe indicates that providing misleading information aimed at undermining the reputation of one drug to the benefit of another drug might constitute a restriction by object (Hoffmann-La Roche)
Concurrences
This site uses cookies to enhance functionality and performance. You may change your cookie settings at any time. If you do nothing, you are giving implied consent to the use of cookies on this website.